Literature DB >> 20000869

Long-term developmental outcome of children of women with epilepsy, unexposed or exposed prenatally to antiepileptic drugs: a meta-analysis of cohort studies.

Ryan Banach1, Radinka Boskovic, Thomas Einarson, Gideon Koren.   

Abstract

Results of studies investigating the long-term effects of intra-uterine exposure to antiepileptic drugs (AEDs) on cognitive functioning are limited and conflicting. To estimate intellectual development of children prenatally exposed or unexposed to AEDs by assessing IQ scores in a systematic review and meta-analysis. A literature search using Pubmed, EMBASE and Google Scholar from inception to 30 April 2009 was performed to identify all original cohort studies that investigated cognitive functioning after in utero exposure to AEDs. Studies had to include at least one group exposed to an AED and one unexposed group. Data from drug exposed and unexposed controls were combined using a random effects model. Eleven studies met the inclusion criteria. Eight studies (three for valproic acid and five for carbamazepine) evaluated IQ as a measure of cognitive development. IQ was assessed by the Wechsler, Bayley or McCarthy intelligence scales, depending on age. One study investigated phenytoin and one study investigated phenobarbital (phenobarbitone). Because one study was reported in two different publications, seven studies were included in the meta-analysis. In total, the seven selected studies included 67 children exposed in utero to valproic acid and 151 exposed to carbamazepine, and 494 unexposed controls born to healthy women or to women with untreated epilepsy. The mean full-scale IQ (FSIQ), verbal IQ (VIQ) and performance IQ (PIQ) scores in children exposed to valproic acid in utero were 83.9 (95% CI 64.2, 103.6), 93.7 (95% CI 72.6, 114.7) and 88.3 (95% CI 69.9, 106.9), respectively. The mean FSIQ, VIQ and PIQ scores in the control group were 102 (95% CI 90, 116), 101 (95% CI 87, 114) and 99 (95% CI 90, 117), respectively. The mean FSIQ, VIQ and PIQ were all significantly lower in the valproic acid group compared with the unexposed group. The FSIQ and VIQ of children exposed to carbamazepine were not statistically different from those of the unexposed control group. In a sub-analysis of carbamazepine exposure in three studies using the Wechsler intelligence scale, PIQ was significantly lower in children exposed to carbamazepine than in unexposed children. Although our analysis revealed no evidence that untreated maternal epilepsy was associated with a lower IQ in the child, there may have been confounding factors, such as milder epilepsy, in this group. Exposure to valproic acid in pregnancy is associated with significantly reduced intelligence in children whose mothers were treated for epilepsy. Exposure to carbamazepine in pregnancy does not appear to be associated with reduced FSIQ and VIQ in children, although PIQ was lower in the sub-analysis. Clinicians should inform families of the potential cognitive adverse effects of valproic acid. More studies are needed to corroborate these findings.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20000869     DOI: 10.2165/11317640-000000000-00000

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  16 in total

1.  Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents.

Authors:  S Koch; K Titze; R B Zimmermann; M Schröder; U Lehmkuhl; H Rauh
Journal:  Epilepsia       Date:  1999-09       Impact factor: 5.864

2.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

Review 3.  Major malformations with valproic acid.

Authors:  Gideon Koren; Alejandro A Nava-Ocampo; Myla E Moretti; Reuven Sussman; Irena Nulman
Journal:  Can Fam Physician       Date:  2006-04       Impact factor: 3.275

4.  Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy.

Authors:  A Ornoy; E Cohen
Journal:  Arch Dis Child       Date:  1996-12       Impact factor: 3.791

5.  Neuropsychological effects of exposure to anticonvulsant medication in utero.

Authors:  J Vinten; N Adab; U Kini; J Gorry; J Gregg; G A Baker
Journal:  Neurology       Date:  2005-03-22       Impact factor: 9.910

6.  Additional educational needs in children born to mothers with epilepsy.

Authors:  N Adab; A Jacoby; D Smith; D Chadwick
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-01       Impact factor: 10.154

7.  Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth.

Authors:  J C S Dean; H Hailey; S J Moore; D J Lloyd; P D Turnpenny; J Little
Journal:  J Med Genet       Date:  2002-04       Impact factor: 6.318

8.  Children exposed to valproate in utero--population based evaluation of risks and confounding factors for long-term neurocognitive development.

Authors:  Kai Eriksson; Katriina Viinikainen; Anne Mönkkönen; Marja Aikiä; Pirkko Nieminen; Seppo Heinonen; Reetta Kälviäinen
Journal:  Epilepsy Res       Date:  2005-07       Impact factor: 3.045

9.  In utero exposure to phenobarbital and intelligence deficits in adult men.

Authors:  J M Reinisch; S A Sanders; E L Mortensen; D B Rubin
Journal:  JAMA       Date:  1995-11-15       Impact factor: 56.272

10.  Antiepileptic medication in pregnancy: late effects on the children's central nervous system development.

Authors:  M C van der Pol; M Hadders-Algra; H J Huisjes; B C Touwen
Journal:  Am J Obstet Gynecol       Date:  1991-01       Impact factor: 8.661

View more
  18 in total

1.  The use of central nervous system active drugs during pregnancy.

Authors:  Bengt Källén; Natalia Borg; Margareta Reis
Journal:  Pharmaceuticals (Basel)       Date:  2013-10-10

Review 2.  Spina bifida in pregnancy: A review of the evidence for preconception, antenatal, intrapartum and postpartum care.

Authors:  Kenga Sivarajah; Sophie Relph; Radha Sabaratnam; Spyros Bakalis
Journal:  Obstet Med       Date:  2018-05-17

Review 3.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

4.  Is carbamazepine safe to take during pregnancy?

Authors:  Jeremy Matlow; Gideon Koren
Journal:  Can Fam Physician       Date:  2012-02       Impact factor: 3.275

Review 5.  Pharmacological treatment of migraine during pregnancy and breastfeeding.

Authors:  Siri Amundsen; Hedvig Nordeng; Kateřina Nezvalová-Henriksen; Lars Jacob Stovner; Olav Spigset
Journal:  Nat Rev Neurol       Date:  2015-04       Impact factor: 42.937

Review 6.  The long-term safety of antiepileptic drugs.

Authors:  Athanasios Gaitatzis; Josemir W Sander
Journal:  CNS Drugs       Date:  2013-06       Impact factor: 5.749

7.  Exposure to antiepileptic drugs in utero and child development: a prospective population-based study.

Authors:  Gyri Veiby; Anne K Daltveit; Synnve Schjølberg; Camilla Stoltenberg; Anne-Siri Øyen; Stein E Vollset; Bernt A Engelsen; Nils E Gilhus
Journal:  Epilepsia       Date:  2013-07-19       Impact factor: 5.864

Review 8.  An Update on Maternal Use of Antiepileptic Medications in Pregnancy and Neurodevelopment Outcomes.

Authors:  Elizabeth E Gerard; Kimford J Meador
Journal:  J Pediatr Genet       Date:  2015-06

9.  Isoflurane-induced apoptosis of oligodendrocytes in the neonatal primate brain.

Authors:  Ansgar M Brambrink; Stephen A Back; Art Riddle; Xi Gong; Matthew D Moravec; Gregory A Dissen; Catherine E Creeley; Krikor T Dikranian; John W Olney
Journal:  Ann Neurol       Date:  2012-10       Impact factor: 10.422

10.  Antiepileptic drug clearance and seizure frequency during pregnancy in women with epilepsy.

Authors:  T L Reisinger; M Newman; D W Loring; P B Pennell; K J Meador
Journal:  Epilepsy Behav       Date:  2013-08-02       Impact factor: 2.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.